음압상처치료(NPWT) 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 창상 유형별, 최종 용도별, 지역별, 부문별 예측(2026-2033년)

Negative Pressure Wound Therapy Market Summary

The global negative pressure wound therapy market size was estimated at USD 2.79 billion in 2025 and is projected to reach USD 4.54 billion by 2033, growing at a CAGR of 6.29% from 2026 to 2033. The market is primarily driven by the rising incidence of chronic wounds and surgical procedures, particularly among aging populations and patients with diabetes or obesity.

The growing clinical preference for advanced wound care solutions that accelerate healing, reduce infection risk, and shorten hospital stays is further supporting their adoption. In addition, technological advancements, such as portable and disposable NPWT systems, are expanding use beyond hospitals into home-care settings. Increasing healthcare expenditure and greater awareness of evidence-based wound management are also contributing to sustained market growth.

The rising incidence of chronic wounds, including diabetic foot ulcers, pressure ulcers, and venous leg ulcers, is a key driver of the negative pressure wound therapy industry. The increasing diabetes prevalence and an aging population lead to more complex, slow-healing wounds that often respond poorly to conventional care. NPWT offers improved healing outcomes and lower complication risks, encouraging greater adoption by healthcare providers and driving sustained demand for NPWT devices and dressings.

The rising number of hospital admissions is a key driving factor in the negative pressure wound therapy industry, as it expands the number of patients requiring advanced wound management for surgical incisions, trauma, pressure ulcers, and chronic wounds. Higher admission rates lead to greater volumes of complex procedures and post-operative care, where NPWT is commonly used to reduce complications and speed healing. As hospitals prioritize shorter length of stay and better outcomes, NPWT adoption increases as a standard component of inpatient wound care.

The increasing volume of surgical procedures and traumatic injuries is another factor driving growth in the negative pressure wound therapy industry, as such wounds often require advanced management to prevent complications. NPWT promotes faster healing, lowers infection risk, and improves post-operative outcomes, making it a preferred solution across surgical and trauma care settings.

According to the World Population Review, in 2024, the number of surgical procedures was approximately 2.0 million, while non-surgical procedures accounted for about 4.2 million cases.

The growing clinical evidence highlighting the effectiveness of negative pressure wound therapy is a key driver of market growth. Numerous trials and real-world studies have demonstrated that NPWT promotes faster wound closure, improves granulation tissue formation, and reduces infection risk compared with traditional dressings. This strong clinical validation has increased clinician confidence, leading to broader adoption across hospitals, outpatient centers, and home care settings, and supporting its inclusion in standard wound care protocols.

The expansion of wound care manufacturing facilities is correlated with the growing evidence supporting the efficacy of NPWT. For instance, in September 2025, Molnlycke Health Care, a global MedTech provider headquartered in Gothenburg, Sweden, announced the groundbreaking of a major expansion of its wound care manufacturing facility in Brunswick, Maine, U.S. This milestone marks the beginning of a USD135 million investment aimed at substantially expanding Molnlycke's manufacturing capacity in the U.S.

"This expansion is a bold step forward for Molnlycke in the U.S. It reinforces our mission to free patients and caregivers from the burden of wounds, strengthens supply resilience, and helps us to deliver high-quality wound care solutions faster, smarter, and more sustainably," says Zlatko Rihter, CEO of Molnlycke. "I'm proud to mark this milestone for Molnlycke, for Maine, and for the future of MedTech."

"Today isn't just about breaking ground. It's about being bold, embracing partnerships and leading with passion," says Chris Biddle, General Manager of U.S. Manufacturing, Wound Care. "Thank you to everyone who helped bring this vision to reality. The expansion is a win for Molnlycke, for the local community and, ultimately, for the patients we serve."

Global Negative Pressure Wound Therapy Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis on the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global negative pressure wound therapy market report based on the product, wound type, end-use, and region:

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Conventional NPWT Devices
• Portable/Disposable NPWT
  • Disposable Portable NPWT
  • Reusable Portable NPWT
• NPWT Accessories
• Wound Type Outlook (Revenue, USD Million, 2021 - 2033)
• Acute Wound
  • Surgical & Traumatic Wounds
  • Burns
• Chronic Wound
  • Diabetic Foot Ulcers
  • Pressure Ulcers
  • Venous Leg Ulcers
  • Other Chronic Wounds
• End-use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals
• Specialty Clinics
• Home Healthcare
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Sweden
  • Denmark
  • Norway
  • Germany
  • UK
  • France
  • Italy
  • Spain
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
  • 1.1.1. Product
  • 1.1.2. Wound Type
  • 1.1.3. End Use
  • 1.1.4. Regional scope
  • 1.1.5. Estimates and forecast timeline
• 1.2. Market Definitions
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
• 1.5. Details of primary research
  • 1.5.1. Data for primary interviews in North America
  • 1.5.2. Data for primary interviews in Europe
  • 1.5.3. Data for primary interviews in Asia Pacific
  • 1.5.4. Data for primary interviews in Latin America
  • 1.5.5. Data for Primary interviews in MEA
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.1.1. Approach 1: Commodity flow approach
  • 1.7.2. Volume price analysis (Model 2)
    • 1.7.2.1. Approach 2: Volume price analysis
• 1.8. Research Scope and Assumptions
  • 1.8.1. List of Secondary Sources
  • 1.8.2. List of Primary Sources
  • 1.8.3. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Negative Pressure Wound Therapy Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Drivers Analysis
    • 3.2.1.1. Increasing chronic wound patients
    • 3.2.1.2. Accumulating evidence of NPWT's efficacy
    • 3.2.1.3. Spread of disposable NPWT for home/post-acute care
  • 3.2.2. Market Restraints Analysis
    • 3.2.2.1. Complications associated with NPWT devices
  • 3.2.3. Market Opportunity Analysis
    • 3.2.3.1. Development of specialized dressings for different wound types
    • 3.2.3.2. Expanded use in surgical fields (prophylactic NPWT for incisions)
    • 3.2.3.3. NPWT diffusion strategy in developing countries
  • 3.2.4. Market Challenge Analysis
    • 3.2.4.1. Treatment cost
    • 3.2.4.2. Limitations in insurance reimbursement policies
    • 3.2.4.3. Training for healthcare professionals
    • 3.2.4.4. Adaptation for difficult wound types
• 3.3. Negative Pressure Wound Therapy Market Analysis Tools
  • 3.3.1. Porter's Analysis
    • 3.3.1.1. Bargaining power of the suppliers
    • 3.3.1.2. Bargaining power of the buyers
    • 3.3.1.3. Threats of substitution
    • 3.3.1.4. Threats from new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic and Social landscape
    • 3.3.2.3. Technological landscape
    • 3.3.2.4. Environmental landscape
    • 3.3.2.5. Legal landscape

Chapter 4. Negative Pressure Wound Therapy Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Negative Pressure Wound Therapy Market: Product Movement Analysis, 2025 & 2033 (USD Million)
• 4.3. Global Negative Pressure Wound Therapy Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
• 4.4. Conventional NPWT Devices
  • 4.4.1. Conventional NPWT devices market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 4.5. Portable/Disposable NPWT
  • 4.5.1. Portable/disposable NPWT market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.5.2. Disposable portable NPWT
    • 4.5.2.1. Disposable portable NPWT market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.5.3. Reusable portable NPWT
    • 4.5.3.1. Reusable portable NPWT market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 4.6. NPWT Accessories
  • 4.6.1. NPWT accessories market revenue estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 5. Negative Pressure Wound Therapy Market: Wound Type Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Negative Pressure Wound Therapy Market: Wound Type Movement Analysis, 2025 & 2033 (USD Million)
• 5.3. Global Negative Pressure Wound Therapy Market Size & Trend Analysis, by Wound Type 2021 to 2033 (USD Million)
• 5.4. Acute Wound
  • 5.4.1. Acute wound market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 5.4.2. Surgical & traumatic wounds
    • 5.4.2.1. Surgical & traumatic wounds market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 5.4.3. Burns
    • 5.4.3.1. Burns market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 5.5. Chronic Wound
  • 5.5.1. Chronic Wound market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 5.5.2. Diabetic foot ulcers
    • 5.5.2.1. Diabetic foot ulcers market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 5.5.3. Pressure ulcers
    • 5.5.3.1. Pressure ulcers market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 5.5.4. Venous leg ulcers
    • 5.5.4.1. Venous leg ulcers market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 5.5.5. Other chronic wounds
    • 5.5.5.1. Other chronic wounds market revenue estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 6. Negative Pressure Wound Therapy Market: End Use Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global Negative Pressure Wound Therapy Market: End use Movement Analysis, 2025 & 2033 (USD Million)
• 6.3. Global Negative Pressure Wound Therapy Market Size & Trend Analysis, by End use 2021 to 2033 (USD Million)
• 6.4. Hospitals
  • 6.4.1. Hospitals market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 6.5. Specialty Clinics
  • 6.5.1. Specialty clinics market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 6.6. Home Healthcare
  • 6.6.1. Home healthcare market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 6.7. Others
  • 6.7.1. Others market revenue estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 7. Negative Pressure Wound Therapy Market: Regional Estimates & Trend Analysis by Product, Wound Type and End Use

• 7.1. Regional Dashboard
• 7.2. Market Size and Trend Analysis, 2021 to 2033
• 7.3. North America
  • 7.3.1. North America negative pressure wound therapy market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.3.2. U.S.
    • 7.3.2.1. Key country dynamics
    • 7.3.2.2. Competitive scenario
    • 7.3.2.3. Regulatory framework
    • 7.3.2.4. Reimbursement scenario
    • 7.3.2.5. U.S. negative pressure wound therapy market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.3.3. Canada
    • 7.3.3.1. Key country dynamics
    • 7.3.3.2. Competitive scenario
    • 7.3.3.3. Regulatory framework
    • 7.3.3.4. Reimbursement scenario
    • 7.3.3.5. Canada negative pressure wound therapy market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.3.4. Mexico
    • 7.3.4.1. Key country dynamics
    • 7.3.4.2. Competitive scenario
    • 7.3.4.3. Regulatory framework
    • 7.3.4.4. Reimbursement scenario
    • 7.3.4.5. Mexico negative pressure wound therapy market estimates and forecasts, 2021 - 2033 (USD Million)
• 7.4. Europe
  • 7.4.1. Europe negative pressure wound therapy market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.4.2. UK
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Competitive scenario
    • 7.4.2.3. Regulatory framework
    • 7.4.2.4. Reimbursement scenario
    • 7.4.2.5. UK negative pressure wound therapy market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.4.3. Germany
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Competitive scenario
    • 7.4.3.3. Regulatory framework
    • 7.4.3.4. Reimbursement scenario
    • 7.4.3.5. Germany negative pressure wound therapy market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.4.4. France
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Competitive scenario
    • 7.4.4.3. Regulatory framework
    • 7.4.4.4. Reimbursement scenario
    • 7.4.4.5. France negative pressure wound therapy market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.4.5. Italy
    • 7.4.5.1. Key country dynamics
    • 7.4.5.2. Competitive scenario
    • 7.4.5.3. Regulatory framework
    • 7.4.5.4. Reimbursement scenario
    • 7.4.5.5. Italy negative pressure wound therapy market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.4.6. Spain
    • 7.4.6.1. Key country dynamics
    • 7.4.6.2. Competitive scenario
    • 7.4.6.3. Regulatory framework
    • 7.4.6.4. Reimbursement scenario
    • 7.4.6.5. Spain negative pressure wound therapy market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.4.7. Sweden
    • 7.4.7.1. Key country dynamics
    • 7.4.7.2. Competitive scenario
    • 7.4.7.3. Regulatory framework
    • 7.4.7.4. Reimbursement scenario
    • 7.4.7.5. Sweden negative pressure wound therapy market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.4.8. Denmark
    • 7.4.8.1. Key country dynamics
    • 7.4.8.2. Competitive scenario
    • 7.4.8.3. Regulatory framework
    • 7.4.8.4. Reimbursement scenario
    • 7.4.8.5. Denmark negative pressure wound therapy market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.4.9. Norway
    • 7.4.9.1. Key country dynamics
    • 7.4.9.2. Competitive scenario
    • 7.4.9.3. Regulatory framework
    • 7.4.9.4. Reimbursement scenario
    • 7.4.9.5. Norway negative pressure wound therapy market estimates and forecasts, 2021 - 2033 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Asia Pacific negative pressure wound therapy market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.5.2. China
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Competitive scenario
    • 7.5.2.3. Regulatory framework
    • 7.5.2.4. Reimbursement scenario
    • 7.5.2.5. China negative pressure wound therapy market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.5.3. Japan
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Competitive scenario
    • 7.5.3.3. Regulatory framework
    • 7.5.3.4. Reimbursement scenario
    • 7.5.3.5. Japan negative pressure wound therapy market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.5.4. India
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Competitive scenario
    • 7.5.4.3. Regulatory framework
    • 7.5.4.4. Reimbursement scenario
    • 7.5.4.5. India negative pressure wound therapy market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.5.5. South Korea
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Competitive scenario
    • 7.5.5.3. Regulatory framework
    • 7.5.5.4. Reimbursement scenario
    • 7.5.5.5. South Korea negative pressure wound therapy market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.5.6. Australia
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Competitive scenario
    • 7.5.6.3. Regulatory framework
    • 7.5.6.4. Reimbursement scenario
    • 7.5.6.5. Australia negative pressure wound therapy market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.5.7. Thailand
    • 7.5.7.1. Key country dynamics
    • 7.5.7.2. Competitive scenario
    • 7.5.7.3. Regulatory framework
    • 7.5.7.4. Reimbursement scenario
    • 7.5.7.5. Thailand negative pressure wound therapy market estimates and forecasts, 2021 - 2033 (USD Million)
• 7.6. Latin America
  • 7.6.1. Latin America negative pressure wound therapy market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.6.2. Brazil
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Competitive scenario
    • 7.6.2.3. Regulatory framework
    • 7.6.2.4. Reimbursement scenario
    • 7.6.2.5. Brazil negative pressure wound therapy market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.6.3. Argentina
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Competitive scenario
    • 7.6.3.3. Regulatory framework
    • 7.6.3.4. Reimbursement scenario
    • 7.6.3.5. Argentina negative pressure wound therapy market estimates and forecasts, 2021 - 2033 (USD Million)
• 7.7. Middle East and Africa
  • 7.7.1. Middle East and Africa negative pressure wound therapy market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.7.2. South Africa
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Competitive scenario
    • 7.7.2.3. Regulatory framework
    • 7.7.2.4. Reimbursement scenario
    • 7.7.2.5. South Africa negative pressure wound therapy market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.7.3. Saudi Arabia
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Competitive scenario
    • 7.7.3.3. Regulatory framework
    • 7.7.3.4. Reimbursement scenario
    • 7.7.3.5. Saudi Arabia negative pressure wound therapy market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.7.4. UAE
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Competitive scenario
    • 7.7.4.3. Regulatory framework
    • 7.7.4.4. Reimbursement scenario
    • 7.7.4.5. UAE negative pressure wound therapy market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.7.5. Kuwait
    • 7.7.5.1. Key country dynamics
    • 7.7.5.2. Competitive scenario
    • 7.7.5.3. Regulatory framework
    • 7.7.5.4. Reimbursement scenario
    • 7.7.5.5. Kuwait negative pressure wound therapy market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis by Key Market Participants
• 8.2. Company Categorization
• 8.3. Company Market Share Analysis, 2025
• 8.4. Company Heat Map Analysis
• 8.5. Strategy Mapping
  • 8.5.1. Expansion
  • 8.5.2. Mergers & Acquisition
  • 8.5.3. Partnerships & Collaborations
  • 8.5.4. New Type Launches
  • 8.5.5. Research and Development
  • 8.5.6. Company Profiles
  • 8.5.7. Smith & Nephew
    • 8.5.7.1. Company overview
    • 8.5.7.2. Financial performance
    • 8.5.7.3. Product Benchmarking
    • 8.5.7.4. Strategic initiatives
  • 8.5.8. Direct Healthcare Group
    • 8.5.8.1. Company overview
    • 8.5.8.2. Financial performance
    • 8.5.8.3. Product Benchmarking
    • 8.5.8.4. Strategic initiatives
  • 8.5.9. Convatec
    • 8.5.9.1. Company overview
    • 8.5.9.2. Financial performance
    • 8.5.9.3. Product Benchmarking
    • 8.5.9.4. Strategic initiatives
  • 8.5.10. DeRoyal Industries, Inc.
    • 8.5.10.1. Company overview
    • 8.5.10.2. Financial performance
    • 8.5.10.3. Product Benchmarking
    • 8.5.10.4. Strategic initiatives
  • 8.5.11. Medela (Medaxis LLC)
    • 8.5.11.1. Company overview
    • 8.5.11.2. Financial performance
    • 8.5.11.3. Product Benchmarking
    • 8.5.11.4. Strategic initiatives
  • 8.5.12. Paul Hartmann AG
    • 8.5.12.1. Company overview
    • 8.5.12.2. Financial performance
    • 8.5.12.3. Product Benchmarking
    • 8.5.12.4. Strategic initiatives
  • 8.5.13. Molnlycke Health Care AB
    • 8.5.13.1. Company overview
    • 8.5.13.2. Financial performance
    • 8.5.13.3. Product Benchmarking
    • 8.5.13.4. Strategic initiatives
  • 8.5.14. 3M (Solventum)
    • 8.5.14.1. Company overview
    • 8.5.14.2. Financial performance
    • 8.5.14.3. Product Benchmarking
    • 8.5.14.4. Strategic initiatives
  • 8.5.15. Cardinal Health
    • 8.5.15.1. Company overview
    • 8.5.15.2. Financial performance
    • 8.5.15.3. Product Benchmarking
    • 8.5.15.4. Strategic initiatives
  • 8.5.16. Genadyne Biotechnologies, Inc.
    • 8.5.16.1. Company overview
    • 8.5.16.2. Financial performance
    • 8.5.16.3. Product Benchmarking
    • 8.5.16.4. Strategic initiatives
  • 8.5.17. Pensar Medical (Lion Street Medical, LLC)
    • 8.5.17.1. Company overview
    • 8.5.17.2. Financial performance
    • 8.5.17.3. Product Benchmarking
    • 8.5.17.4. Strategic initiatives
  • 8.5.18. Alleva Medical Ltd.
    • 8.5.18.1. Company overview
    • 8.5.18.2. Financial performance
    • 8.5.18.3. Product Benchmarking
    • 8.5.18.4. Strategic initiatives
  • 8.5.19. Guard Medical
    • 8.5.19.1. Company overview
    • 8.5.19.2. Financial performance
    • 8.5.19.3. Product Benchmarking
    • 8.5.19.4. Strategic initiatives
  • 8.5.20. Triage Meditech Pvt. Ltd
    • 8.5.20.1. Company overview
    • 8.5.20.2. Financial performance
    • 8.5.20.3. Product Benchmarking
    • 8.5.20.4. Strategic initiatives
  • 8.5.21. L&R Group
    • 8.5.21.1. Company overview
    • 8.5.21.2. Financial performance
    • 8.5.21.3. Product Benchmarking
    • 8.5.21.4. Strategic initiatives
  • 8.5.22. Essity Aktiebolag (publ)
    • 8.5.22.1. Company overview
    • 8.5.22.2. Financial performance
    • 8.5.22.3. Product Benchmarking
    • 8.5.22.4. Strategic initiatives